Current Report Filing (8-k)
November 09 2016 - 7:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 9, 2016
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-30929
|
|
13-4087132
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
One Marina Park Drive, 12
th
Floor
Boston, Massachusetts 02210
(Address of Principal Executive Offices)
(617) 466-3500
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 9, 2016, Keryx
Biopharmaceuticals, Inc. (Keryx) issued a press release announcing its results of operations for the third quarter ended September 30, 2016. Keryx also announced that on November 9, 2016 at 8:00 a.m. ET, it will host an
investor conference call to discuss its third quarter financial results and provide a business update. A copy of such press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference. A copy of the investor
presentation to be used on the investor conference call is being furnished as Exhibit 99.2 to this report and is incorporated herein by reference.
The information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.
|
Financial Statements And Exhibits.
|
The following exhibits are furnished herewith:
|
|
|
99.1
|
|
Press release issued by Keryx Biopharmaceuticals, Inc., dated November 9, 2016.
|
|
|
99.2
|
|
Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on November 9, 2016.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Keryx Biopharmaceuticals, Inc.
(Registrant)
|
|
|
|
|
Date: November 9, 2016
|
|
|
|
By:
|
|
/s/ Brian Adams
|
|
|
|
|
|
|
Brian Adams
|
|
|
|
|
|
|
General Counsel and Corporate Secretary
|
INDEX TO EXHIBITS
|
|
|
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release issued by Keryx Biopharmaceuticals, Inc., dated November 9, 2016.
|
|
|
99.2
|
|
Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on November 9, 2016.
|
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024